帕博利珠单抗联合贝伐珠单抗及口服节拍环磷酰胺治疗重度经治铂耐药卵巢癌的真实世界疗效
客观缓解率为7.5%,疾病控制率60%,24周临床获益率30.0%,中位无进展生存期3.3个月,中位总生存期7.8个月。结论认为该方案客观缓解率低,临床角色已收窄,但可能仍适用于无法接受或已进展于随机证据支持疗法的特定患者。
要点
- 真实世界重度经治铂耐药卵巢癌中,该联合方案客观缓解率仅7.5%。
- 疾病控制率60%,24周临床获益率30.0%,中位PFS 3.3个月,中位OS 7.8个月。
- 仅可考虑用于无法接受或已进展于随机证据支持疗法的特定患者。
核心结论
- 该联合方案在真实世界重度经治铂耐药卵巢癌中客观缓解率低,临床角色已因FDA批准的新方案而收窄。
- 对于无法接受或已进展于随机证据支持疗法的特定患者,该方案可能仍为合适选择。
研究设计与样本
- 单中心回顾性研究,纳入2019年1月至2025年4月接受帕博利珠单抗联合贝伐珠单抗及口服节拍环磷酰胺治疗的铂耐药或难治性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。
主要发现
- 中位年龄65岁,75.6%为高级别浆液性组织学,既往平均接受3.6线治疗。
- 客观缓解率7.5%,52.5%达疾病稳定,疾病控制率60%,24周临床获益率30.0%。
- 中位无进展生存期3.3个月,中位总生存期7.8个月。
- 三分之二患者发生不良事件,12.5%患者因毒性停用至少一种药物。
临床怎么用
- 在重度经治铂耐药卵巢癌中,该方案客观缓解率低,不应作为优先选择。
- 仅可考虑用于无法接受或已进展于随机证据支持疗法的特定患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinical efficacy and tolerability of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated patients with platinum-resistant ovarian cancer in a real-world setting. METHODS: This retrospective study included patients with platinum-resistant or refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treated with pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide at a single academic institution from January 2019 through April 2025. The primary endpoint was the objective response rate. Secondary endpoints included the disease control rate, clinical benefit rate at 24 weeks, progression-free survival, overall survival, and treatment discontinuation due to toxicity. RESULTS: Forty patients were evaluable for response and toxicity. Median age was 65 years, and 75.6% had high-grade serous histology. Patients were heavily pretreated with a mean of 3.6 prior lines of therapy. The objective response rate was 7.5%, while 52.5% achieved stable disease, yielding a disease control rate of 60%. The clinical benefit rate at 24 weeks was 30.0%. Median progression free survival was 3.3 months and median overall survival was 7.8 months. Two-thirds of patients experienced adverse events with 12.5% of patients discontinuing at least 1 drug due to toxicity. CONCLUSIONS: This regimen produced a low objective response rate in a real-world cohort. With the emergence of newer FDA-approved regimens for PROC, the clinical role of pembrolizumab, bevacizumab, and oral cyclophosphamide has narrowed. However, it may remain an appropriate option for select patients who are ineligible for or have progressed after therapies supported by randomized evidence.
引用
- Smith G, Petty A, Krivanek K, et al. Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer. Gynecol Oncol. 2026. PMID: 42822082. doi:10.1016/j.ygyno.2026.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。